Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: A Childrens Cancer Group study

Medical and Pediatric Oncology

Volumn 27, Issue 1, 1996, Pages 15-20

  Lange, Beverly J ^a,c   Blatt, Julie ^b   Sather, Harland N ^c   Meadows, Anna T ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^c CHILDREN S ONCOLOGY GROUP   (United States)

Author keywords

acute lymphoblastic leukemia; intermediate risk ALL; methotrexate

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; FOLINIC ACID; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CHILDHOOD LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

6-MERCAPTOPURINE; ADMINISTRATION, ORAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; CHILD; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SPINAL; LEUCOVORIN; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MALE; METHOTREXATE; PREDNISONE; RISK FACTORS; SURVIVAL ANALYSIS; VINCRISTINE;

EID: 0029978820     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-911X(199607)27:1<15::AID-MPO4>3.0.CO;2-X     Document Type: Article

References (31)

1. Aur RJA, Simone JV, Hustsu HO, et al: Central nervous system therapy and combination chemotherapy of childhood lymphocytic leukemia. Blood 37:272-281, 1971.
2. Sather H, Miller D, Nesbit M, Heyn R, Hammond DG: Differences in prognosis for boys and girls with acute lymphoblastic leukemia. Lancet 1:739-743, 1981.
3. Nesbit ME, Sather HN, Robison LL, Ortega JA, Hammond GD: Randomized Study of 3 years vs. 5 years of chemotherapy in childhood acute lymphoblastic leukemia. J Clin Oncol 1:308-316, 1983.
4. Coccia PF, Bleyer WA, Siegel SE, et al: Development and preliminary findings of Childrens Cancer Study Group protocols (161, 162, and 163) for low-, average-, and high-risk acute lymphoblastic leukemia in children. In Murphy SB, Gilbert JR (eds): "Leukemia Research: Advances in Cell Biology and Treatment." Amsterdam. Elsevier Science Publishing Co., Inc., 1983, pp. 241-250.
5. Bleyer WA, Sather HN, Nickerson HJ, et al: Monthly pulses of vincristine and prednisone prevent bone marrow and testicular relapse in low-risk childhood acute tymphoblastic leukemia: a report of the CCG-161 study by the Childrens Cancer Study Group. J Clin Oncol 9:1012-1021, 1991.
6. Miller DR, Leikin S, Albo V, Sather H, Karon M, Hammond D: Prognostic factors and therapy in acute lymphoblastic leukemia of childhood: CCG-141. Cancer 51:1041-1049, 1983.
7. Miller DR, Leikin SL, Albo VC, Sather H, Karon MR, Hammond GD: Three versus five years of maintenance therapy are equivalent in childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group J Clin Oncol 7:73-79, 1989.
8. Bennett J, Catovsky D, Daniel MT, et al: The morphological classification of acute lymphoblastic leukemia: concordance among observers and clinical correlations. Br J Haematol 47:553-551, 1981.
9. Moe PJ, Seip M, Finne PH: Intermediate dose methotrexate (IDM) in childhood acute lymphocytic leukemia in Norway. Report on a national treatment program. Acta Paediatr Scand 70:73-79, 1981.
10. Lange B, Burroughs B, Meadows A, Burkey E: Home care involving methotrexate infusions for children with acute lymphoblastic leukemia. J Pediatr 112:492-495, 1988.
11. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958.
12. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163-170, 1966.
13. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II. Analysis and examples. Br J Cancer 35:1-39, 1977.
14. Jolivet J, Cowan KH, Curt GA, Clendeninn NJ, Chabner BA: The pharmacology and clinical use of methotrexate. N Engl J Med 309:1094-1104, 1983
15. Evans WE, Crom WR, Abromowitch M, et al: Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia; identification of a relation between concentration and effect. N Engl J Med 314:471-477, 1986.
16. Pearson A, Amineddine HA, Yule M, et al: The influence of serum methotrexate concentrations and drug dosage on outcome in childhood acute lymphoblastic leukaemia. Br J Cancer 64:169-173, 1991.
17. Schmeigelow K: Prognostic significance of methotrexate and 6-mercaptopurine dosage during maintenance chemotherapy for childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol 8:301-312, 1991.
18. Freeman AI, Weinberg V, Brecher ML, et al: Comparison of intermediate-dose methotrexate with cranial irradiation for the post-induction treatment of acute lymphocytic leukemia in children. N Engl J Med 308:477-484, 1983.
19. Green DM, Brecher ML, Blumenson LE, Grossi M, Freeman AI: The use of intermediate dose methotrexate in increased risk childhood acute lymphoblastic leukemia. Cancer 50:2722-2727, 1982.
20. Koizumi S, Fujimoto T, Takeda T, et al: Comparison of intermittent or continuous methotrexate plus 6-mercaptopurine in regimens for standard-risk acute lymphoblastic leukemia in childhood (JCCLSG-S811). Cancer 61:1292-1300, 1988.
21. Moe PJ, Seip M, Finne PH, Kolsmannskog S: Intermediate dose methotrexate in childhood acute lymphoblastic leukemia. Eur Pediatr Haematol Oncol 1:113-119, 1984.
22. Wang JJ, Freeman AI, Sinks LF: Treatment of acute lymphocytic leukemia by high dose intravenous methotrexate. Cancer Res 36: 1441-1444, 1976.
23. Frankel LS, Wang YM, Shuster J, Nitschke R, Doering EJ, Pullen J: High-dose methotrexate as part of remission maintenance therapy for childhood acute lymphocytic leukemia: a Pediatric Oncology Group Pilot Study. J Clin Oncol 1:804-809, 1983.
24. Pui CH, Simone JV, Hancock ML, et al: Impact of three methods of treatment intensification on acute lymphoblastic leukemia in children: long-term results of St. Jude total therapy study. Leukemia 6:150-156, 1992.
25. Chessels JM, Leiper AD, Tiedemann K, Hardisty RM, Richards S: Oral methotrexate is as effective as intramuscular in maintenance therapy of acute lymphoblastic leukemia. Arch Dis Child 62:172-176, 1987.
26. Aur RJA, Hustu HO, Verzosa MS, Wood A, Simone JV: Comparison of two methods of preventing central nervous system leukemia. Blood 42:349-357, 1973.
27. Henze G, Langermann HJ, Ritter J: Treatment strategy for different risk groups in childhood acute lymphoblastic leukemia: a report from the BFM Study Group. Hematol Blut Transfus 26:87-93, 1981.
28. Clavell LA, Gelber RD, Cohen HJ, et al: Four-agent induction and intensive asparaginase therapy for treatment of acute lymphoblastic leukemia of childhood. N Engl J Med 315:657-663, 1986.
29. Camitta B, Leventhal B, Lauer S, et al: Intermediate dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B, acute lymphocytic leukemia of childhood: a Pediatric Oncology Group Study. J Clin Oncol 7:1539-1544, 1989.
30. Tubergen DG, Gilchrist GS, O'Brien RT, et al: Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group Phase III trial. J Clin Oncol 11:527-537, 1993.
31. Tubergen DG, Gilchrist GS, O'Brien RT, et al: Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: a Childrens Cancer Group report. J Clin Oncol 11:520-526, 1993.